A Comparative Study of the Efficacy of Detach(R) Versus Zinc Oxide to Control Post-Weaning Diarrhoea in Piglets

Presents at Australasian Pig Science Association Conference
Presents at Australasian Pig Science Association Conference
Sydney, Nov 21, 2017 AEST (ABN Newswire) - At the Australasian Pig Science Association (APSA) Conference in Melbourne this week, Dr Trish Holyoake & Dr Tracey Mynott presented a poster highlighting the comparable efficacy of a single dose of Anatara's (ASX:ANR) Detach(R) product to in-feed Zinc oxide (ZnO) in reducing diarrhoea and antibiotic treatments in post-weaning piglets. These results are significant given the push to remove ZnO from the food chain.


Anatara Lifesciences is currently applying for re-registration of Detach(R) as an alternative to antibiotics and Zinc Oxide (ZnO) to aid in the control of pre- and post-weaning diarrhoea in piglets. Bromelain, the active in Detach(R) reduces diarrhoea through its anti-attachment and anti-secretory effect (see Notes 1, 2 below) on the intestine, and is therefore unlikely to contribute to antimicrobial resistance. This study was designed to compare the efficacy of a single 4mL Detach(R) drench at weaning (18-28 days of age) to ZnO (2,500 ppm in feed) as an aid in the control of post-weaning diarrhoea in piglets.


A single dose of Detach(R) at weaning was as effective as in-feed ZnO in reducing diarrhoea and antibiotic treatments in piglets post-weaning compared to untreated piglets.


Literature Cited:

1 Chandler DS, Mynott TL (1998) Gut 43, 196-202;

2 Mynott TL, Guandalini S, Raimondi F, Fasano A (1997) Gastroenterology 113, 175-184

To view tables and figures, please visit:

About Anatara Lifesciences Ltd

Anatara Lifesciences ASX ANRAnatara Lifesciences (ASX:ANR) is developing therapeutics for gastrointestinal diseases in production animals and humans. Its lead product Detach(R) is a natural plant based product that aids in the control of diarrhoea and will help address global concerns around the overuse of antibiotics in production animals that is contributing to the rise of so-called "super bugs" that make infectious diseases harder to treat. The Anatara team has a strong track record in biological science as well as building and growing international biotech companies.



Investor inquiries:
Dr Mel Bridges
Chairman & CEO
Anatara Lifesciences
Phone: +61-413-051-600
Email: mbridges@anataralifesciences.com

Media inquiries:
Jane Lowe
IR Department
Phone: +61-411-117-774
Email: jane.lowe@irdepartment.com.au

Related Companies

Anatara Lifesciences Ltd

ABN Newswire This Page Viewed:  (Last 7 Days: 21) (Last 30 Days: 117) (Since Published: 2331) 

Anatara Lifesciences Ltd NEWS: RECENT VISITS (3573)

Research Report

Social Media